Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb;13(1):47-70.
doi: 10.2217/nmt-2021-0058. Epub 2022 Oct 31.

Updates and advances in multiple sclerosis neurotherapeutics

Moein Amin  1 , Carrie M Hersh  2
Affiliations
Review

Updates and advances in multiple sclerosis neurotherapeutics

Moein Amin et al. Neurodegener Dis Manag. 2023 Feb.

Abstract

The multiple sclerosis (MS) neurotherapeutic landscape is rapidly evolving. New disease-modifying therapies (DMTs) with improved efficacy and safety, in addition to an expanding pipeline of agents with novel mechanisms, provide more options for patients with MS. While treatment of MS neuroinflammation is well tailored in the existing DMT armamentarium, concerted efforts are currently underway for identifying neuropathological targets and drug discovery for progressive MS. There is also ongoing research to develop agents for remyelination and neuroprotection. Further insights are needed to guide DMT initiation and sequencing as well as to determine the role of autologous stem cell transplantation in relapsing and progressive MS. This review provides a summary of these updates.

Keywords: BTK inhibitors; autologous hematopoietic stem cell transplantation; disease-modifying therapy; early highly effective therapy; escalation therapy; multiple sclerosis; neuroprotective agents; progressive multiple sclerosis; relapsing multiple sclerosis; remyelinating therapies.

Plain language summary

The range of treatment options available for multiple sclerosis (MS) is growing, with the aim of developing safer and more effective therapies. There are ongoing efforts to discover additional mechanisms of MS and create drugs that can target these pathways. A more tailored approach will allow better personalization of drug selection for patients. There is currently a special focus on identifying treatment targets for progressive MS, where there are only a limited number of therapeutic options available to date. In addition, there is ongoing research aimed at developing stem cell therapies, drugs that provide neuroprotection and agents that can potentially reverse the damage caused by MS through remyelination. In this review, these topics are summarized.

PubMed Disclaimer

Conflict of interest statement

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

References

    1. Browne P, Chandraratna D, Angood C et al. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology 83, 1022–1024 (2014). - PMC - PubMed
    1. Wallin MT, Culpepper WJ, Campbell JD et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology 92, e1029–e1040 (2019). - PMC - PubMed
    1. Ascherio A. Environmental factors in multiple sclerosis. Expert Rev. Neurother. 13, 3–9 (2013). - PubMed
    1. Bjornevik K, Cortese M, Healy BC et al. Longitudinal analysis reveals high prevalence of Epstein–Barr virus associated with multiple sclerosis. Science 375, 296–301 (2022). - PubMed
    1. Miclea A, Bagnoud M, Chan A, Hoepner R. A brief review of the effects of vitamin D on multiple sclerosis. Front. Immunol. 11, 781 (2020). - PMC - PubMed

Publication types

MeSH terms